Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BBIO
Nasdaq
2834
https://bridgebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for BridgeBio Pharma Inc
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- May 15th, 2024 11:30 am
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
- May 14th, 2024 11:30 am
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
- May 13th, 2024 11:30 am
What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
- May 4th, 2024 1:26 pm
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
- May 3rd, 2024 10:44 am
BridgeBio Oncology Therapeutics launches with $200m funding
- May 3rd, 2024 10:22 am
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- May 2nd, 2024 11:30 am
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
- May 2nd, 2024 11:00 am
BridgeBio spinout launches with $200M for KRAS cancer drugs
- May 2nd, 2024 7:00 am
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
- May 1st, 2024 12:10 pm
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
- Apr 25th, 2024 2:02 pm
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Apr 7th, 2024 5:15 pm
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
- Mar 27th, 2024 1:25 pm
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
- Mar 6th, 2024 4:53 am
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
- Mar 5th, 2024 5:58 pm
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- Mar 4th, 2024 9:17 pm
BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
- Mar 4th, 2024 9:05 pm
Bayer pays $310M to buy into BridgeBio heart drug
- Mar 4th, 2024 8:00 am
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
- Mar 4th, 2024 7:30 am
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- Mar 4th, 2024 7:30 am
Scroll